EOFlow EOPatch (GlucoMen Day PUMP)
EOFlow (distributed in Europe by A. Menarini Diagnostics)
A fully tubeless, disposable, app-controlled patch pump — the world's second after Omnipod — sold in Europe as the GlucoMen Day PUMP. A Unified Patent Court ruling banned and recalled it across 17 European countries in 2025 for infringing an Insulet patent.
The scorecard
Controlled by its own Narsha smartphone app; a Diabeloop DBLG1 automated-insulin-delivery partnership was announced but never reached patients at scale before the device was pulled.[2]
CE-marked since 2021 with roughly 69,000 units sold in Europe, but limited published clinical reliability data and the program was halted by litigation rather than by a safety signal.[3]
Fully tubeless, disposable patch pump — small (49.5 x 39 x 14.5 mm), light (26g without insulin) and water-resistant; one of only two such pumps ever commercialized.[1]
Operated entirely from the Narsha smartphone app with no separate handheld controller — marketed in Europe as the first patch pump with app-based control.[1]
200-unit reservoir of rapid-acting U100 insulin over ~3.5 days of wear, twice-weekly replacement; smaller than the 300-unit reservoirs of some rivals.[1]
Effectively unavailable: a July 2025 Unified Patent Court ruling banned sales and ordered a recall across 17 European countries for infringing Insulet's patent, after an earlier 2023 German suspension.[3]
The full picture
The EOFlow EOPatch — sold in Europe by Menarini as the GlucoMen Day PUMP — was, on paper, a genuine rival to Omnipod: a fully tubeless, disposable patch pump controlled entirely from a smartphone app called Narsha, with no separate handheld and no tubing. It was compact and light (26g empty), water-resistant, held a 200-unit reservoir of rapid-acting insulin, and was worn for about 3.5 days, making it the world's second commercialized disposable patch pump after Omnipod. Launched on a CE mark from 2021, it reached around 69,000 users across Europe, and a partnership with Diabeloop aimed to turn it into a wearable automated insulin delivery system using the DBLG1 algorithm. That future never arrived. Insulet pursued EOFlow for patent and trade-secret infringement, a $738M Medtronic acquisition collapsed, and in July 2025 the Unified Patent Court ordered the pump banned and recalled across 17 European countries for infringing an Insulet patent, with daily penalties for further sales. It is included here as a notable, instructive case: a credible tubeless pump removed from the market by litigation, not by clinical failure, and effectively unavailable to patients today.
Sources
- [1]EOFlow receives CE Mark for its innovative wearable insulin pump · manufacturer · 2021-05-25
- [2]Diabeloop and EOFlow partner to offer a Wearable AID with a Smartphone App · manufacturer
- [3]UPC hands rare default win to Insulet, bans insulin pump in EU · news · 2025-07-24